Immuno-oncology Drugs Market

The Immuno-oncology Drugs Market is expanding as advances in cancer treatment increasingly focus on therapies that stimulate or enhance the immune system's ability to fight cancer. Immuno-oncology has become an important area of cancer therapy, supported by developments in drug discovery, clinical research, and the growing number of immuno-oncology treatments progressing through clinical trials. According to Maximize Market Research, the market was valued at USD 35.12 billion in 2025 and is expected to reach USD 110.75 billion by 2032, growing at a CAGR of 17.83% from 2026 to 2032.

The increasing global prevalence of cancer, rising adoption of immunotherapies, growing use of biological and targeted drug therapies, and an expanding geriatric population are supporting market development. Increasing regulatory approvals for immuno-oncology therapies are also encouraging pharmaceutical companies to invest in research and development. The market is witnessing growing interest in therapies capable of producing durable tumor responses, while advances in personalized treatment approaches are creating opportunities for new immuno-oncology products and technologies.

* Get Actionable Market Insights: https://www.maximizemarketresearch.com/request-sample/98268/ 

Market Growth Drivers

• Increasing prevalence of cancer: The growing number of cancer patients worldwide is creating greater demand for innovative and effective treatment options.
• Rising adoption of immunotherapy: Immunotherapies are gaining greater acceptance as an alternative or complementary approach to traditional chemotherapy.
• Advances in drug discovery: Technological developments in cancer research and drug development are supporting the introduction of new immuno-oncology therapies.
• Growing clinical research: A rising number of immuno-oncology treatments in clinical development is expanding the potential treatment pipeline.
• Increasing regulatory approvals: FDA approvals of immuno-oncology therapies are supporting the acceptance and commercialization of new treatments.
• Growth of targeted therapies: Increasing adoption of biological and targeted drug therapies is supporting innovation within cancer treatment.
• Expanding geriatric population: The growing elderly population is contributing to demand for cancer diagnosis and treatment.

Key Market Segments

The Immuno-oncology Drugs Market can be segmented based on drug type, disease type, end use, application, and region. Major drug types include immune checkpoint inhibitors, monoclonal antibodies, cytokine-based immunotherapy, cancer vaccines, CAR-T cell therapy, and others. Disease categories include melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others. End users include hospitals, clinics, ambulatory surgical centers, and others.

By drug type, the immune checkpoint inhibitors segment is expected to hold a dominant market share during the forecast period. These therapies have demonstrated success across multiple malignancies and represent one of the most established classes of immuno-oncology agents. The CAR-T cell therapy segment is also expected to witness lucrative growth, supported by increasing cancer prevalence and demand for effective treatment approaches.

Immuno-oncology Drugs Market Key players:
1. Amgen Inc.
2. AstraZeneca Plc
3. Bristol Myers Squibb Company
4. AbbVie Inc.
5. Eli Lilly and Company
6. Sanofi
7. F. Hoffmann-La Roche Ltd.
8. Genentech, Inc.
9. Novartis AG
10. Pfizer Inc.
11. Johnson & Johnson
12. Merck & Co., Inc.
13. Merck KGaA
14. GSK Plc
15. Regeneron Pharmaceuticals, Inc.
16. Bayer AG
17. Ipsen
18. Bluebird Bio, Inc.
19. Agenus Inc.
20. BeiGene Ltd.
21. Incyte Corporation
22. Seagen Inc.
23. Moderna, Inc.
24. BioNTech SE
25. Exelixis, Inc.

Emerging Trends

• Expansion of immune checkpoint inhibitors: Continued clinical success across multiple cancer types is supporting the development and adoption of checkpoint inhibitor therapies.
• Growth of CAR-T cell therapy: Advances in cell-based cancer treatment are creating opportunities for personalized immuno-oncology therapies.
• Increasing focus on personalized treatment: Immuno-oncology therapies are increasingly being developed around differences in patient immune responses and tumor characteristics.
• Growth of targeted therapies: Biological and targeted drug development is contributing to innovation in cancer treatment.
• Expansion of clinical pipelines: More immuno-oncology candidates are progressing through different phases of clinical trials.
• Increasing use of combination therapies: Pharmaceutical companies are developing treatment strategies that combine immuno-oncology agents with other therapeutic approaches.
• Advances in drug discovery: Technological developments are supporting the identification and development of new immuno-oncology treatment options.

Recent Developments

• Merck & Co. Keytruda approval: On February 10, 2026, Merck & Co. received FDA approval for Keytruda in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer, expanding the clinical application of the PD-1 inhibitor.
• Janssen Rybrevant Faspro approval: On December 17, 2025, Janssen Biotech obtained FDA approval for Rybrevant Faspro, a subcutaneous bispecific antibody for patients with EGFR-mutated NSCLC, providing an alternative administration approach.
• Daiichi Sankyo Datroway approval: On June 23, 2025, Daiichi Sankyo received accelerated FDA approval for Datroway, a TROP-2-directed antibody-drug conjugate for EGFR-mutated NSCLC.
• Janssen Akeega approval: On December 12, 2025, Janssen Biotech secured FDA approval for Akeega for BRCA2-mutated metastatic castration-sensitive prostate cancer, reflecting continued development of biomarker-driven cancer therapies.
• Pfizer encorafenib approval: On February 24, 2026, Pfizer received traditional FDA approval for encorafenib in combination with chemotherapy for BRAF V600E-mutated metastatic colorectal cancer.
• Expansion of advanced oncology research: Pharmaceutical companies and research organizations continue to invest in immuno-oncology research, clinical trials, targeted therapies, and personalized treatment approaches.

Regional Outlook

North America is expected to hold a larger share of the global Immuno-oncology Drugs Market during the forecast period, followed by Europe. The region benefits from pharmaceutical research, clinical development, regulatory approvals, advanced healthcare infrastructure, and growing adoption of innovative cancer therapies.

Europe is expected to remain an important market, supported by pharmaceutical research, cancer-treatment development, and increasing adoption of advanced therapies. The region follows North America in the MMR market outlook.

Asia-Pacific is expected to be the fastest-growing regional market during the forecast period. Improving medical infrastructure, increasing patient awareness, and rising disposable income are supporting the adoption of advanced cancer treatments. The high prevalence of cancers such as melanoma, lung, bladder, stomach, and esophageal cancers in parts of the region is also contributing to opportunities for immuno-oncology therapies.

Middle East & Africa and South America are also included in the MMR market assessment. Opportunities in these regions are associated with healthcare development, increasing access to advanced cancer treatments, and the broader expansion of immuno-oncology therapies.

Related Reports: 

Venous Stents Market https://www.maximizemarketresearch.com/market-report/venous-stents-market/231857/ 

mRNA vaccines Market https://www.maximizemarketresearch.com/market-report/mrna-vaccines-market/213483/ 

Pupillometer Market https://www.maximizemarketresearch.com/market-report/pupillometer-market/213391/ 

Conclusion

The Global Immuno-oncology Drugs Market is undergoing significant development as cancer prevalence, advances in drug discovery, clinical research, and regulatory approvals increase demand for innovative treatment approaches. The market is projected to reach USD 110.75 billion by 2032, with immune checkpoint inhibitors maintaining a dominant position and CAR-T cell therapy offering significant growth opportunities. Continued pharmaceutical investment, personalized treatment development, targeted therapies, and expansion of clinical pipelines are expected to create further opportunities across the global immuno-oncology landscape.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com